Search research articles
Contact Us
Filters
Showing results (931-940 of 1,012) with videos related to
Page
of 102
Sort By:
Journal of Cancer Research and Clinical Oncology
|
April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Human Pathology
|
November 26, 2010
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo
Daniela Massi, Cristina Fondi, Chiara Nozzoli, et al.
Tissue & Cell
|
October 1, 2021
BEWO trophoblast cells and Toxoplasma gondii infection modulate cell death mechanisms in THP-1 monocyte cells by interference in the expression of death receptor and intracellular proteins
Andressa da Silva Castro, Mariana Bodini Angeloni, Bellisa de Freitas Barbosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Blood
|
April 14, 2012
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo, Lucia Pantani, Maria Teresa Petrucci, et al.
Annals of Hematology
|
March 28, 2019
Use of eltrombopag in aplastic anemia in Europe
Matyas Ecsedi, Étienne Lengline, Cora Knol-Bout, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, et al.
BMC Cancer
|
November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework
Mario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Eclinicalmedicine
|
July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
Elena Zamagni, Stefania Oliva, Francesca Gay, et al.
Bone Marrow Transplantation
|
September 3, 2022
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide
Jacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.
Page
of 102
Search research articles
Search
Showing results (931-940 of 1,012) with videos related to
Sort By:
Page
of 102
Journal of Cancer Research and Clinical Oncology
|
April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Human Pathology
|
November 26, 2010
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo
Daniela Massi, Cristina Fondi, Chiara Nozzoli, et al.
Tissue & Cell
|
October 1, 2021
BEWO trophoblast cells and Toxoplasma gondii infection modulate cell death mechanisms in THP-1 monocyte cells by interference in the expression of death receptor and intracellular proteins
Andressa da Silva Castro, Mariana Bodini Angeloni, Bellisa de Freitas Barbosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Blood
|
April 14, 2012
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo, Lucia Pantani, Maria Teresa Petrucci, et al.
Annals of Hematology
|
March 28, 2019
Use of eltrombopag in aplastic anemia in Europe
Matyas Ecsedi, Étienne Lengline, Cora Knol-Bout, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, et al.
BMC Cancer
|
November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework
Mario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Eclinicalmedicine
|
July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
Elena Zamagni, Stefania Oliva, Francesca Gay, et al.
Bone Marrow Transplantation
|
September 3, 2022
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide
Jacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.
Page
of 102